CC
IGMS

Corton Capital’s IGM Biosciences IGMS Stock Holding History

Corton Capital’s Portfolio IGMS Stock Details IGMS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-66,768
Closed -$1.1M – 495
2024
Q3 		$1.1M Buy
66,768
+3,432
+5% +$37.6K 0.54% 2
2024
Q2 		$435K Buy
+63,336
New +$542K 0.23% 75
2022
Q4 		– Sell
-9,999
Closed -$227K – 341
2022
Q3 		$227K Buy
+9,999
New +$202K 0.28% 164

Other funds holding IGMS

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
S
Sanofi Paris, France $336M AUM 126.85% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Corton Capital's IGMS Position: Q4 2024 in Review

Corton Capital sold out of IGM Biosciences (IGMS) in Q4 2024, closing a stake of 66,768 shares — an estimated $1.1M sold.

Corton Capital first reported a position in IGMS in Q3 2022 and held it in 3 quarters. The position peaked at $1.1M in Q3 2024. 85 funds tracked by Wall St. Rank hold IGMS as of Q4 2024.

  • Corton Capital reported no remaining IGM Biosciences position as of Q4 2024 after selling out during the quarter.
  • Corton Capital sold 66,768 IGM Biosciences shares in Q4 2024, an estimated $1.1M.
  • Corton Capital first reported a position in IGM Biosciences in Q3 2022 and held it in 3 quarters.
  • Corton Capital's IGM Biosciences position peaked at $1.1M in Q3 2024.
  • 85 funds tracked by Wall St. Rank held IGM Biosciences as of Q4 2024.

Based on Corton Capital's 13F filing for Q4 2024, filed 14 Feb 2025.